Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of $1.56, $0.10 worse than the analyst estimate of $1.66. Revenue for the quarter came in at $44.84 million versus the consensus estimate of $26.1 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.